• Je něco špatně v tomto záznamu ?

Role of carbonyl reducing enzymes in the phase I biotransformation of the non-steroidal anti-inflammatory drug nabumetone in vitro

L. Skarydova, M. Nobilis, V. Wsól,

. 2013 ; 43 (4) : 346-54.

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc14064253

1. Nabumetone is a clinically used non-steroidal anti-inflammatory drug, its biotransformation includes major active metabolite 6-methoxy-2-naphtylacetic acid and another three phase I as well as corresponding phase II metabolites which are regarded as inactive. One important biotransformation pathway is carbonyl reduction, which leads to the phase I metabolite, reduced nabumetone. 2. The aim of this study is the determination of the role of a particular human liver subcellular fraction in the nabumetone reduction and the identification of participating carbonyl reducing enzymes along with their stereospecificities. 3. Both subcellular fractions take part in the carbonyl reduction of nabumetone and the reduction is at least in vitro the main biotransformation pathway. The activities of eight cytosolic carbonyl reducing enzymes--CBR1, CBR3, AKR1B1, AKR1B10, AKR1C1-4--toward nabumetone were tested. Except for CBR3, all tested reductases transform nabumetone to its reduced metabolite. AKR1C4 and AKR1C3 have the highest intrinsic clearances. 4. The stereospecificity of the majority of the tested enzymes is shifted to the production of an (+)-enantiomer of reduced nabumetone; only AKR1C1 and AKR1C4 produce predominantly an (-)-enantiomer. This project provides for the first time evidence that seven specific carbonyl reducing enzymes participate in nabumetone metabolism.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc14064253
003      
CZ-PrNML
005      
20140708083812.0
007      
ta
008      
140704s2013 enk f 000 0|eng||
009      
AR
024    7_
$a 10.3109/00498254.2012.720048 $2 doi
035    __
$a (PubMed)23020786
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Skarydova, Lucie $u Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Králové, Charles University in Prague, Czech Republic.
245    10
$a Role of carbonyl reducing enzymes in the phase I biotransformation of the non-steroidal anti-inflammatory drug nabumetone in vitro / $c L. Skarydova, M. Nobilis, V. Wsól,
520    9_
$a 1. Nabumetone is a clinically used non-steroidal anti-inflammatory drug, its biotransformation includes major active metabolite 6-methoxy-2-naphtylacetic acid and another three phase I as well as corresponding phase II metabolites which are regarded as inactive. One important biotransformation pathway is carbonyl reduction, which leads to the phase I metabolite, reduced nabumetone. 2. The aim of this study is the determination of the role of a particular human liver subcellular fraction in the nabumetone reduction and the identification of participating carbonyl reducing enzymes along with their stereospecificities. 3. Both subcellular fractions take part in the carbonyl reduction of nabumetone and the reduction is at least in vitro the main biotransformation pathway. The activities of eight cytosolic carbonyl reducing enzymes--CBR1, CBR3, AKR1B1, AKR1B10, AKR1C1-4--toward nabumetone were tested. Except for CBR3, all tested reductases transform nabumetone to its reduced metabolite. AKR1C4 and AKR1C3 have the highest intrinsic clearances. 4. The stereospecificity of the majority of the tested enzymes is shifted to the production of an (+)-enantiomer of reduced nabumetone; only AKR1C1 and AKR1C4 produce predominantly an (-)-enantiomer. This project provides for the first time evidence that seven specific carbonyl reducing enzymes participate in nabumetone metabolism.
650    _2
$a alkoholoxidoreduktasy $x metabolismus $7 D000429
650    _2
$a antiflogistika nesteroidní $x chemie $x metabolismus $7 D000894
650    _2
$a biokatalýza $x účinky léků $7 D055162
650    _2
$a biotransformace $x účinky léků $7 D001711
650    _2
$a butanony $x chemie $x metabolismus $7 D002074
650    _2
$a lidé $7 D006801
650    _2
$a kinetika $7 D007700
650    _2
$a játra $x účinky léků $x enzymologie $7 D008099
650    12
$a I. fáze biotransformace $7 D050216
650    _2
$a NADP $x farmakologie $7 D009249
650    _2
$a stereoizomerie $7 D013237
650    _2
$a subcelulární frakce $x účinky léků $x metabolismus $7 D013347
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Nobilis, Milan
700    1_
$a Wsól, Vladimir
773    0_
$w MED00004746 $t Xenobiotica; the fate of foreign compounds in biological systems $x 1366-5928 $g Roč. 43, č. 4 (2013), s. 346-54
856    41
$u https://pubmed.ncbi.nlm.nih.gov/23020786 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20140704 $b ABA008
991    __
$a 20140708084102 $b ABA008
999    __
$a ok $b bmc $g 1031737 $s 862985
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2013 $b 43 $c 4 $d 346-54 $i 1366-5928 $m Xenobiotica $n Xenobiotica $x MED00004746
LZP    __
$a Pubmed-20140704

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...